HCWB (HCW Biologics) Buyback Yield % : -15.82 (As of Dec. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

HCW Biologics's current buyback yield was -15.82%.

HCW Biologics Buyback Yield % Historical Data

The historical data trend for HCW Biologics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Buyback Yield % Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

-67.52

-0.02

-0.05

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Buyback Yield %	Get a 7-Day Free Trial															-	-0.13	-15.12	-	-

Competitive Comparison of HCW Biologics's Buyback Yield %

For the Biotechnology subindustry, HCW Biologics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Buyback Yield % falls into.

HCW Biologics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

HCW Biologics's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0.024)	/	44.1307475
	=	-0.05%

HCW Biologics's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	20.40194196
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.

HCW Biologics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

HCW Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057